XML 144 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Other disclosures (Tables)
 12 Months Ended
Dec. 31, 2022
Additional information [abstract]  
Share-based payment expensed in the income statement
Share-based payment expensed in the income statement
DKK million202220212020
Restricted stock units to employees265189189
Long-term share-based incentive programme (Management Board)1
250234162
Long-term share-based incentive programme (management group below Management Board)819598436
Shares allocated to individual employees2051936
Share-based payment expensed in the income statement1,5391,040823
1. In 2021, Novo Nordisk introduced a new share-based compensation programme with terms, which amortises the grant date valuation over three years (2019 and 2020 programmes were amortised over four years). The 2022 expense includes amortisation of the 2019, 2020, 2021 and 2022 programmes.

Outstanding restricted stock units (million)Restricted stock units
to employees		Shares for
Management Board		Shares for management group below Management BoardShares allocated to
individual employees		Total
202220212020202220212020202220212020202220212020202220212020
Outstanding at the beginning
of the year		2.0 2.1 2.1 2.2 1.8 1.3 5.5 4.5 3.2 0.2 0.2 0.3 9.9 8.6 6.9 
Released allocated shares(0.0)(0.1)(0.0)(0.5)(0.3)(0.1)(1.2)(0.6)(0.2)(0.1)(0.1)(0.1)(1.8)(1.1)(0.4)
Cancelled allocated shares— — — (0.1)0.0 (0.0)(0.2)(0.3)(0.1)(0.0)(0.0)(0.0)(0.3)(0.3)(0.1)
Allocated in the year0.4 — — 0.4 0.5 0.4 1.7 1.6 1.0 0.4 0.1 — 2.9 2.2 1.4 
Performance adjustment2
— — — — 0.2 0.2 — 0.3 0.6 — — — — 0.5 0.8 
Outstanding at the end of the year2.4 2.0 2.1 2.0 2.2 1.8 5.8 5.5 4.5 0.5 0.2 0.2 10.7 9.9 8.6 
2. The number of shares for Management Board and management group below Management Board has been adjusted as the targets set by the Board are expected to be exceeded for the 2019, 2020, 2021 and 2022 programmes.
Contractual obligations not recognised in the balance sheet
Contractual obligations not recognised in the balance sheet
DKK million (Undiscounted)CurrentNon-currentTotal
2022
Leases1
205 1,641 1,846
Research and development obligations5,988 7,582 13,570
Research and development – potential milestone payments2
376 5,011 5,387
Commercial product launch – potential milestone payments2
— 7,598 7,598
Purchase obligations relating to investments in property, plant and equipment1,696 1,427 3,123
Other purchase obligations18,762 14,366 33,128
Total obligations not recognised in the balance sheet27,027 37,625 64,652
2021
Leases1
145 636 781 
Research and development obligations4,196 6,357 10,553 
Research and development – potential milestone payments2
771 4,220 4,991 
Commercial product launch – potential milestone payments2
— 5,966 5,966 
Purchase obligations relating to investments in property, plant and equipment545 — 545 
Other purchase obligations13,407 5,998 19,405 
Total obligations not recognised in the balance sheet19,064 23,177 42,241 
1. Predominantly relates to estimated variable property taxes, leases committed but not yet commenced and low value leases.
2. Potential milestone payments are associated with uncertainty as they are linked to successful achievements in research activities.
Material transactions with related parties
Material transactions with related parties
DKK million202220212020
Novo Holdings A/S
Purchase of Novo Nordisk B shares6,9846,6955,963
Dividend payment to Novo Holdings A/S7,2076,1445,767
NNIT Group
Services provided by NNIT660593775
Dividend payment from NNIT—(4)(18)
Novozymes Group
Services provided by Novo Nordisk(78)(116)(113)
Services provided by Novozymes927872
Fee to statutory auditors
DKK million202220212020
Statutory audit1
382626
Audit-related services233
Tax advisory services349
Other services1244
Total fee to statutory auditors553742
1. 2022 statutory audit fee includes DKK 9 million of additional fee related to 2021.
Companies in the Novo Nordisk Group
Company and countryActivity
Parent company
Novo Nordisk A/S, Denmark••••
Subsidiaries by geographical area
Company and countryPercentage of shares ownedActivity
North America Operations
Novo Nordisk Canada Inc., Canada100•
Novo Nordisk Inc., US100•
Novo Nordisk North America Operations A/S, Denmark100•
Novo Nordisk Pharmaceutical Industries LP, US100•
Novo Nordisk Pharmatech US, Inc., US100•
Novo Nordisk Pharma, Inc., US100•
Novo Nordisk Research Center Indianapolis, Inc., US100•
Novo Nordisk Research Center Seattle, Inc., US100•
Novo Nordisk US Bio Production, Inc., US100•
Novo Nordisk US Commercial Holdings, Inc., US100•
Novo Nordisk US Holdings Inc., US100•
Corvidia Therapeutics, Inc., US100•
Dicerna Pharmaceuticals, Inc., US100•
Emisphere Technologies, Inc., US100•
Forma Therapeutics, Inc., US100•
Region International Operations
Novo Nordisk Pharmaceuticals A/S, Denmark100•
Novo Nordisk Pharma Operations A/S, Denmark100••
Novo Nordisk Region AAMEO and LATAM A/S, Denmark100•
Novo Nordisk Region Europe A/S, Denmark100•
Novo Nordisk Region Japan & Korea A/S, Denmark100•
Region EMEA
Aldaph SpA, Algeria100••
Novo Nordisk Pharma GmbH, Austria100•
S.A. Novo Nordisk Pharma N.V., Belgium100•
Novo Nordisk Pharma d.o.o., Bosnia and Herzegovina100•
Novo Nordisk Pharma EAD, Bulgaria100•
Novo Nordisk Hrvatska d.o.o., Croatia100•
Novo Nordisk s.r.o., Czech Republic100•
Novo Nordisk Denmark A/S, Denmark100•
Novo Nordisk Pharmatech A/S, Denmark100••
Novo Nordisk Egypt LLC, Egypt100•
Company and countryPercentage of shares ownedActivity
Novo Nordisk Egypt Pharmaceuticals Ltd., Egypt100•
Novo Nordisk Farma OY, Finland100•
Novo Nordisk, France100•
Novo Nordisk Production SAS, France100•
Novo Nordisk Pharma GmbH, Germany100•
Novo Nordisk Hellas Epe., Greece100•
Novo Nordisk Hungária Kft., Hungary100•
Novo Nordisk Limited, Ireland100•
Novo Nordisk Ltd, Israel100•
Novo Nordisk S.P.A., Italy100•
Novo Nordisk Kazakhstan LLP, Kazakhstan100•
Novo Nordisk Kenya Ltd., Kenya100•
Novo Nordisk Pharma SARL, Lebanon100•
UAB Novo Nordisk Pharma, Lithuania100•
Novo Nordisk Farma dooel, North Macedonia100•
Novo Nordisk Pharma SAS, Morocco100•
Novo Nordisk B.V., Netherlands100•
Novo Nordisk Finance (Netherlands) B.V., Netherlands100•
Novo Nordisk Pharma Limited, Nigeria100•
Novo Nordisk Norway AS, Norway100•
Novo Nordisk Pharmaceutical Services Sp. z.o.o., Poland100•
Novo Nordisk Pharma Sp.z.o.o., Poland100•
Novo Nordisk Portugal, Lda., Portugal100•
Novo Nordisk Farma S.R.L., Romania100•
Novo Nordisk Limited Liability Company, Russia100••
Novo Nordisk Production Support LLC, Russia100•
Novo Nordisk Saudi for Trading, Saudi Arabia100•
Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Serbia100•
Novo Nordisk Slovakia s.r.o., Slovakia100•
Novo Nordisk, d.o.o., Slovenia100•
Novo Nordisk (Pty) Limited, South Africa100•
Novo Nordisk Pharma S.A., Spain100•
Novo Nordisk Scandinavia AB, Sweden100•
Novo Nordisk Health Care AG, Switzerland100•••
Novo Nordisk Pharma AG, Switzerland100•
Novo Nordisk Tunisie SARL, Tunisia100•
Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Turkey100•
Novo Nordisk Ukraine, LLC, Ukraine100•
Novo Nordisk Pharma Gulf FZE, United Arab Emirates100•
Novo Nordisk Holding Limited, UK100•
Novo Nordisk Limited, UK100•
Novo Nordisk Research Centre Oxford Limited, UK100•
Company and countryPercentage of shares ownedActivity
Region China
Novo Nordisk (China) Pharmaceuticals Co. Ltd., China100••
Novo Nordisk (Shanghai) Pharma Trading Co., Ltd., China100•
Novo Nordisk Region China A/S, Denmark100•
Novo Nordisk Hong Kong Limited, Hong Kong100•
Novo Nordisk Pharma (Taiwan) Ltd., Taiwan100•
Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd., China100•
Region Rest of World
Novo Nordisk Pharma Argentina S.A., Argentina100•
Novo Nordisk Pharmaceuticals Pty. Ltd., Australia100•
Novo Nordisk Pharma (Private) Limited, Bangladesh100•
Novo Nordisk Produção Farmacêutica do Brasil Ltda., Brazil100•
Novo Nordisk Farmacêutica do Brasil Ltda., Brazil100•
Novo Nordisk Farmacéutica Limitada, Chile100•
Novo Nordisk Colombia SAS, Colombia100•
Novo Nordisk India Private Limited, India100•
Novo Nordisk Service Centre (India) Pvt. Ltd., India100•
PT. Novo Nordisk Indonesia, Indonesia100•
Novo Nordisk Pars, Iran100••
Novo Nordisk Pharma Ltd., Japan100••
Novo Nordisk Pharma (Malaysia) Sdn Bhd, Malaysia100•
Novo Nordisk Pharma Operations Sdn Bhd, Malaysia100•
Novo Nordisk Mexico S.A. de C.V., Mexico100•
Novo Nordisk Pharmaceuticals Ltd., New Zealand100•
Novo Nordisk Pharma (Private) Limited, Pakistan100•
Novo Nordisk Panama S.A., Panama100•
Novo Nordisk Peru S.A.C., Peru100•
Novo Nordisk Pharmaceuticals (Philippines) Inc., Philippines100•
Novo Nordisk Pharma (Singapore) Pte Ltd., Singapore100•
Novo Nordisk India Holding Pte Ltd., Singapore100•
Novo Nordisk Pharma Korea Ltd., South Korea100•
Novo Nordisk Lanka (PVT) Ltd, Sri Lanka100•
Novo Nordisk Pharma (Thailand) Ltd., Thailand100•
Novo Nordisk Vietnam Ltd., Vietnam100•
Other subsidiaries and associated companies
NNE A/S, Denmark100•
NNIT A/S, Denmark18 •
CS Solar Fund XIV, LLC, US99 •
Companies without significant activities are not included in the list.
NNE A/S subsidiaries are not included in the list.